Open house discount agreements Adalimumab (ATC L04AB04)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 308 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Adalimumab, ATC L04AB04

50/100

Score d'opportunité

Needs reviewLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or framework maximum amount is provided. The actual business volume is unknown.

The open-house contract can be automatically suspended if AOK Bayern enters into a national or regional discount agreem...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Moderate opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Aug 2027
Provision of pharmaceutical product Adalimumab (ATC L04AB04) under a discount agreement with AOK Bayern.
Non-exclusive, open-house model where all eligible pharmaceutical companies can participate.

Afficher le résumé complet

This is an open-house model (not a classic procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Adalimumab (ATC L04AB04). Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and the contract. The agreement runs from September 1, 2025, to August 31, 2027, with the possibility to join at any time until July 3, 2027. No estimated value is provided.

Risques

No estimated value or framework maximum amount is provided. The actual business volume is unknown.

The open-house contract can be automatically suspended if AOK Bayern enters into a national or regional discount agreem...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

Must be a pharmaceutical company.

Administrative

Submit a signed declaration of reliability.
Submit the signed contract and annex listing the covered medicines.

Les exigences peuvent être incomplètes.

Acheteur

Nom

AOK Bayern - Die Gesundheitskasse

Localisation

München, DEU

[email protected]

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements Adalimumab (ATC L04AB04)

Non-exclusive discount agreement for Adalimumab (ATC L04AB04) with a duration from 01.09.2025 to 31.08.2027. All eligible pharmaceutical companies can join. The contract is identical for all participants.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 03, 2027

Détails de la procédure

Date de publication: 13 Jul 2025
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 458658-2025

Documents (2)

Document de consultation 1 Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3